Opakalim for seizures

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 13 Mar 2024: Trial registered, NCT06309966
  2. 13 May 2024: Trial started, NCT06309966
  3. 5 Jun 2024: Trial registered, NCT06443463
  4. 30 Jul 2024: Trial started, NCT06443463

The trials

NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

State
Under way
Phase
Phase 2 and Phase 3
People
390 planned
Started
13 May 2024
Primary completion
Oct 2026
Arms
BHV-7000 50 mg, BHV-7000 75 mg
Results
None posted
  1. 13 Mar 2024: Trial registered
  2. 13 May 2024: Trial started

NCT06443463: Long-term Safety and Tolerability of BHV-7000

State
Under way
Phase
Phase 2
People
660 planned
Started
30 Jul 2024
Primary completion
Dec 2026
Arms
BHV-7000 50 mg, BHV-7000 75 mg
Results
None posted
  1. 5 Jun 2024: Trial registered
  2. 30 Jul 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.